Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression
Archived on March 1, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 1:00 PM EST
- Posted
- January 30, 2026
- Notice type
- Presolicitation
- Set-aside
- No Set aside used
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)
Notice details
- Office
- PROGRAM SUPPORT CENTER ACQ MGMT SVC
- Place of performance
- Philadelphia, Pennsylvania, 19104
- Last updated
- Nov 3, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- NIH-26-006363-IntentNotice
- Notice ID
- 16f0d3a0ac4244809319904e2656f3c7
Description
This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only.
Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.
------------------------------------------------------------------------------------------------------------------------
The intent is to award a contract on a solesource basis for Nucleic acid–based reagents for in vivo transient protein expression for the National Cancer Institute and Center for Cancer Research to:
Trustees of The University of Pennsilvania - Penn Medicine
3451 Walnut Street
Philadelphia, PA
19104, USA
The supplies required are nucleic acid-based reagents.
The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.
Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
- 1Version 1PresolicitationArchived
Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression
- 3Version 3PresolicitationArchivedCurrent
Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
NIH-26-006363-IntentNotice
Archive Date
Mar 1, 2026
Office Address
ROCKVILLE, MD, 20857